{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:44Z","timestamp":1792123664052,"version":"4.4.0"},"reference-count":13,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ocul Oncol Pathol"],"abstract":"<jats:p>&lt;p&gt;Introduction: The aims of the study were to investigate clinical characteristics and spectrum of immune checkpoint inhibitor optic nerve disorders (ICI-OND), including ICI-optic neuritis (ICI-ON), ICI-optic disc edema (ICI-OE), ICI-optic perineuritis, and ICI-panuveitis; to understand the breadth of management options; to investigate long-term outcomes of these patients; and, importantly, to tackle the question of outcomes following rechallenge of these potentially life-preserving drug regimens. Methods: Retrospective analysis, single-center tertiary cancer hospital. Thirty-seven eyes in twenty consecutive patients with ICI-OND treated at Memorial Sloan Kettering Cancer Center between June 16, 2019, and June 5, 2025, were included. Results: In 37 eyes with ICI-OND, the majority of patients had painless loss of vision (85%), bilateral involvement (70%), dyschromatopsia (59%), abnormal testing: visual field (79%), retinal nerve fiber layer optical coherence tomography (80%), and magnetic resonance imaging (56%). Time to diagnosis occurred following a median of 4.5 drug cycles and was shorter with combination ICI (two ICI\u2019s) versus monotherapy (one ICI). The 3 patients with pain all had concurrent intraocular inflammation. Following steroid treatment and ICI cessation, vision was improved in 84% of eyes, stable in 11%, and declined in 5%. Snellen lines regained was associated with baseline vision (p = 0.0002). Five patients were rechallenged, and we did not see nor detect recurrence of ICI-OND in 4 patients; 1 patient had recurrence which resolved with steroids and vision returned to baseline. Conclusions: In the majority of cases, ICI-OND occurs bilaterally with painless vision decline and color vision deficits. Cessation of drug along with initiation of systemic steroids can improve vision to 20\/40 or better in at least one involved eye, and although we included a smaller subset of patients, we found that ICI can be rechallenged after completion of steroids, without documented recurrence of ICI-OND in most patients. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000550281","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:00:54Z","timestamp":1768323654000},"page":"69-80","source":"Crossref","is-referenced-by-count":1,"title":["Drug Rechallenge after Immune Checkpoint Inhibitor-Induced Inflammation and Optic Nerve Disorders"],"prefix":"10.1159","volume":"12","author":[{"given":"Julia","family":"Canestraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7637-3108","authenticated-orcid":false,"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06480-5"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080120057025"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.05.003"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002181"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080120052024"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171981"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231222659"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.16"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-023-10139-6"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad137.157"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12811"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011049"}],"container-title":["Ocular Oncology and Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000550281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:04:29Z","timestamp":1780934669000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000550281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,6,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000550281","archive":["Portico"],"relation":{},"ISSN":["2296-4681","2296-4657"],"issn-type":[{"value":"2296-4681","type":"print"},{"value":"2296-4657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}